Pyxis Oncology annual return on equity
2021
2022
2023
2024
2025
Pyxis Oncology Return on Equity (ROE) Growth & History (PYXS)
Pyxis Oncology's return on equity was −91.43% for fiscal 2025.
View full Pyxis Oncology company overviewPyxis Oncology annual return on equity history
| Fiscal year | Period ended | Return on equity | Change (percentage points) |
|---|---|---|---|
| 2025 | 2025-12-31 | −91.43% | −28.68 pp |
| 2024 | 2024-12-31 | −62.75% | −11.25 pp |
| 2023 | 2023-12-31 | −51.51% | +5.69 pp |
| 2022 | 2022-12-31 | −57.19% | +4.66 pp |
| 2021 | 2021-12-31 | −61.85% | — |
Pyxis Oncology quarterly return on equity
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Return on equity | Change (percentage points) |
|---|---|---|---|
| Q2 2026 | 2026-06-30 | −118.69% | −99.45 pp |
| Q1 2026 | 2026-03-31 | −54.97% | −36.06 pp |
| Q4 2025 | 2025-12-31 | −29.64% | −3.71 pp |
| Q3 2025 | 2025-09-30 | −28.13% | −15.02 pp |
| Q2 2025 | 2025-06-30 | −19.24% | −9.47 pp |
| Q1 2025 | 2025-03-31 | −18.90% | −16.80 pp |
| Q4 2024 | 2024-12-31 | −25.92% | −14.09 pp |
| Q3 2024 | 2024-09-30 | −13.11% | +3.17 pp |
| Q2 2024 | 2024-06-30 | −9.78% | +0.92 pp |
| Q1 2024 | 2024-03-31 | −2.10% | +10.19 pp |
| Q4 2023 | 2023-12-31 | −11.83% | +8.82 pp |
| Q3 2023 | 2023-09-30 | −16.28% | −2.46 pp |
| Q2 2023 | 2023-06-30 | −10.69% | +0.78 pp |
| Q1 2023 | 2023-03-31 | −12.30% | +0.39 pp |
| Q4 2022 | 2022-12-31 | −20.65% | −2.93 pp |
| Q3 2022 | 2022-09-30 | −13.81% | — |
| Q2 2022 | 2022-06-30 | −11.48% | — |
| Q1 2022 | 2022-03-31 | −12.68% | — |
| Q4 2021 | 2021-12-31 | −17.73% | — |
Pyxis Oncology return on equity trends
Between the periods ended 2021-12-31 and 2025-12-31, Pyxis Oncology's return on equity decreased from −61.85% to −91.43%, a change of −29.58 percentage points. The latest reported quarter, Q2 2026, shows −118.69%.
About the metric
What return on equity (ROE) means
Return on equity (ROE) measures how much net income a company generates relative to shareholders’ equity. It can help evaluate how efficiently equity capital is used, but unusually high or negative values may reflect leverage, losses, or a small equity base.
Calculation and source
How return on equity is calculated
TickerStat calculates ROE as SEC-reported net income divided by average stockholders’ equity at the beginning and end of the fiscal period. Periods with missing or non-positive average equity are omitted. Quarterly ROE uses quarterly net income and is not annualized. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Pyxis Oncology source filings ↗